{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T20:44:55Z","timestamp":1772052295770,"version":"3.50.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T00:00:00Z","timestamp":1656806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,31]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Topical steroids are commonly used in treatment of eosinophilic esophagitis (EoE), but currently there is lack of data to clarify most effective regimen. We aimed to study the achievement of histologic remission using the same dose of budesonide in two different delivery formulations. Patients with established EoE treated with pharmacy compounded budesonide capsule or budesonide Rincinol gel (both 3\u00a0mg twice daily) were studied retrospectively. Those with pre-treatment and post-treatment histologic assessment were included with main endpoint being histologic remission. 103 patients (62 gel, 41 capsule) were included, with higher rate of histologic remission with gel (84 vs. 59%, P=0.004). A subset of patients in both groups had lack of steroid response (&amp;lt;50% drop in eosinophils) (15% for gel, 32% for capsule). Formulation\/delivery vehicle of steroid treatments to esophageal mucosa in EoE appears important for treatment efficacy, with budesonide gel having higher likelihood of histologic remission compared to budesonide capsules in our population. A truly steroid refractory group appears likely in our population. Larger, prospective studies may help clarify best regimen of topical steroids in EoE and may work to identify patients likely to benefit from alternative therapies.<\/jats:p>","DOI":"10.1093\/dote\/doac040","type":"journal-article","created":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T06:47:03Z","timestamp":1656830823000},"source":"Crossref","is-referenced-by-count":2,"title":["Histologic response to steroids in eosinophilic esophagitis is dependent on delivery compound"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8952-4577","authenticated-orcid":false,"given":"Daniel A","family":"Schupack","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5942-7816","authenticated-orcid":false,"given":"Kimberly","family":"Johnson","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A","family":"Akambase","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Geno","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crystal","family":"Lavey","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan J","family":"Lennon","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Ravi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana L","family":"Snyder","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A","family":"Katzka","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A","family":"Alexander","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,7,3]]},"reference":[{"issue":"3","key":"2023010614045320900_ref1","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MPG.0b013e3181eb5a9f","article-title":"Variation in prevalence, diagnostic criteria, and initial management options for eosinophilic gastrointestinal diseases in the United States","volume":"52","author":"Spergel","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"2023010614045320900_ref2","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ajg.2014.47","article-title":"Esophageal eosinophilia is increased in rural areas with low population density: results from a national pathology database","volume":"109","author":"Jensen","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"2023010614045320900_ref3","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1053\/j.gastro.2008.02.016","article-title":"Eosinophilic esophagitis: a prevalent disease in the United States that affects all age groups","volume":"134","author":"Kapel","year":"2008","journal-title":"Gastroenterology"},{"issue":"4","key":"2023010614045320900_ref4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.cgh.2013.09.008","article-title":"Prevalence of eosinophilic esophagitis in the United States","volume":"12","author":"Dellon","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2023010614045320900_ref5","doi-asserted-by":"crossref","DOI":"10.1093\/dote\/doy093","article-title":"Food impaction: etiology over 35 years and association with eosinophilic esophagitis","volume":"32","author":"Lenz","year":"2019","journal-title":"Dis Esophagus"},{"issue":"7","key":"2023010614045320900_ref6","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1053\/j.gastro.2012.03.001","article-title":"Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors","volume":"142","author":"Gonsalves","year":"2012","journal-title":"Gastroenterology"},{"issue":"2","key":"2023010614045320900_ref7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.gtc.2014.02.001","article-title":"Steroid treatment of eosinophilic esophagitis in adults","volume":"43","author":"Alexander","year":"2014","journal-title":"Gastroenterol Clin North Am"},{"issue":"10","key":"2023010614045320900_ref8","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/17474124.2020.1785869","article-title":"Recent insights on the use of topical steroids in eosinophilic esophagitis","volume":"14","author":"Reddy","year":"2020","journal-title":"Expert Rev Gastroenterolo Hepatol"},{"issue":"13","key":"2023010614045320900_ref9","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-019-01173-2","article-title":"Pharmacotherapies for the treatment of eosinophilic esophagitis: state of the art review","volume":"79","author":"Rooij","year":"2019","journal-title":"Drugs"},{"issue":"1","key":"2023010614045320900_ref10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1053\/j.gastro.2019.03.025","article-title":"Straumann A and International EOS-1 Study Group. Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial","volume":"157","author":"Lucendo","year":"2019","journal-title":"Gastroenterology"},{"issue":"8","key":"2023010614045320900_ref11","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/apt.15670","article-title":"Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis","volume":"51","author":"Hirano","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"2023010614045320900_ref12","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1053\/j.gastro.2016.11.021","article-title":"and MP-101-06 Investigators. Budesonide oral suspension improves symptomatic, endoscopic, and histologic parameters compared with placebo in patients with eosinophilic esophagitis","volume":"152","author":"Dellon","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"2023010614045320900_ref13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/j.gastro.2019.03.014","article-title":"Efficacy of budesonide vs. fluticasone for initial treatment of eosinophilic esophagitis in a randomized conrolled trial","volume":"157","author":"Dellon","year":"2019","journal-title":"Gastroenterology"},{"issue":"2","key":"2023010614045320900_ref14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10620-020-06192-8","article-title":"Effect of maintenance therapy for eosinophilic esophagitis on need for recurrent dilation","volume":"66","author":"Schupack","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"4","key":"2023010614045320900_ref15","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cgh.2018.05.051","article-title":"Safety and efficacy of budesonide oral suspension maintenance therapy in patients with eosinophilic esophagitis","volume":"17","author":"Dellon","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"2023010614045320900_ref16","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.cgh.2012.03.018","article-title":"Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis","volume":"10","author":"Alexander","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"2023010614045320900_ref17","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1053\/j.gastro.2006.08.033","article-title":"A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis","volume":"131","author":"Konikoff","year":"2006","journal-title":"Gastroenterology"},{"issue":"3","key":"2023010614045320900_ref18","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.cgh.2014.07.034","article-title":"Predictors of response to steroid therapy for eosinophilic esophagitis and treatment of steroid-refractory patients","volume":"13","author":"Wolf","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2023010614045320900_ref19","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/ajg.2012.443","article-title":"Randomized controlled trial comparing aerosoized swallowed fluticasone to esomeprazole for esophageal eosinophilia","volume":"108","author":"Moawad","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"21","key":"2023010614045320900_ref20","first-page":"00456","article-title":"Dellon ES and ORBIT1\/SHP621-301 Investigators. Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: results from a Phase 3 trial","volume":"S1542-3565","author":"Hirano","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2023010614045320900_ref21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1136\/gutjnl-2011-301817","article-title":"Endoscopic assessment of the oesphageal features of eosinophilic oesophagitis: validation of a novel classification and grading system","volume":"62","author":"Hirano","year":"2013","journal-title":"Gut"},{"issue":"4","key":"2023010614045320900_ref22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s40268-018-0253-9","article-title":"Efficacy and safety of budesonide in the treatment of eosinophilic esophagitis: updated systematic review and meta-analysis of randomized and non-randomized studies","volume":"18","author":"Rawla","year":"2018","journal-title":"Drugs R D"},{"issue":"2","key":"2023010614045320900_ref23","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/MPG.0000000000001281","article-title":"A new formulation of oral viscous budesonide in treating paediatric eosinophilic oesophagitis: a pilot study","volume":"64","author":"Olvia","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"2023010614045320900_ref24","first-page":"2509","article-title":"Compounded oral viscous budesonide is effective and provides a durable response in eosinophilic esophagitis","volume":"7","author":"Reed","year":"2018","journal-title":"HSOA J Gastroenterol Hapatol Res"},{"issue":"1","key":"2023010614045320900_ref25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/MPG.0000000000001626","article-title":"Retrospective comparison of fluticasone propionate and oral viscous budesonide in children with eosinophilic esophagitis","volume":"66","author":"Fable","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"2023010614045320900_ref26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/nmo.12753","article-title":"High-resolution manometry in patients with eosinophilic esophagitis under topical steroid therapy \u2013 a prospective observational study (HIMEOS \u2013 study)","volume":"28","author":"Nennstiel","year":"2016","journal-title":"Neurogastroenterol Motil"},{"issue":"1","key":"2023010614045320900_ref27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cgh.2014.05.021","article-title":"Efficacy and safty of oral budesonide suspension in pediatric patients with eosinophilic esophagitis","volume":"13","author":"Gupta","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2023010614045320900_ref28","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/gutjnl-2014-308815","article-title":"A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis","volume":"65","author":"Miehlke","year":"2016","journal-title":"Gut"},{"issue":"5","key":"2023010614045320900_ref29","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1053\/j.gastro.2010.07.048","article-title":"Budesonide is effecetive in adolescent and adult patients with active eosinophilic esophagitis","volume":"139","author":"Straumann","year":"2010","journal-title":"Gastroenterology"},{"issue":"2","key":"2023010614045320900_ref30","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.gastro.2010.05.001","article-title":"Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial","volume":"139","author":"Dohil","year":"2010","journal-title":"Gastroenterology"},{"issue":"2","key":"2023010614045320900_ref31","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.gastro.2014.04.019","article-title":"Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis","volume":"147","author":"Butz","year":"2014","journal-title":"Gastroenterology"},{"issue":"5","key":"2023010614045320900_ref32","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s10620-009-0859-4","article-title":"Comparison of esomeprazole to aerosolized swallowed fluticasone for eosinophilic esophagitis","volume":"55","author":"Peterson","year":"2010","journal-title":"Dig Dis Sci"},{"issue":"7","key":"2023010614045320900_ref33","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S2468-1253(18)30096-7","article-title":"Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study","volume":"3","author":"Shoda","year":"2018","journal-title":"The Lancet Gastroenterology and Hepatology"},{"issue":"6","key":"2023010614045320900_ref34","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.gie.2015.11.019","article-title":"The extremely narrow-caliber esophagus is a treatment-resistant subphenotype of eosinophilic esophagitis","volume":"83","author":"Eluri","year":"2016","journal-title":"Gastrointest Endosc"}],"container-title":["Diseases of the Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/36\/1\/doac040\/48468135\/doac040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/36\/1\/doac040\/48468135\/doac040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T14:09:03Z","timestamp":1673014143000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/dote\/article\/doi\/10.1093\/dote\/doac040\/6627605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,3]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,7,3]]},"published-print":{"date-parts":[[2022,12,31]]}},"URL":"https:\/\/doi.org\/10.1093\/dote\/doac040","relation":{},"ISSN":["1120-8694","1442-2050"],"issn-type":[{"value":"1120-8694","type":"print"},{"value":"1442-2050","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1]]},"published":{"date-parts":[[2022,7,3]]},"article-number":"doac040"}}